0304 Lilly diabetes
BioCentury & Flourish

Product Development

Lilly’s tirzepatide more potent than Novo’s semaglutide, but higher discontinuation: Data Byte

Mar 5, 2021 | 2:10 AM GMT

Head-to-head and cross-trial comparisons indicate Lilly’s tirzepatide bests Novo’s semaglutide

Read the full 353 word article

How to gain access

Continue reading with a
two-week free trial.